Growth Metrics

Apellis Pharmaceuticals (APLS) Debt to Equity (2024 - 2025)

Apellis Pharmaceuticals filings provide 2 years of Debt to Equity readings, the most recent being $1.23 for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 21.8% year-over-year to $1.23, compared with a TTM value of $1.23 through Dec 2025, down 21.8%, and an annual FY2025 reading of $1.23, down 21.8% over the prior year.
  • Debt to Equity hit $1.23 in Q4 2025 for Apellis Pharmaceuticals, up from $1.13 in the prior quarter.
  • The five-year high for Debt to Equity was $2.31 in Q2 2025, with the low at $1.13 in Q3 2025.